How a specific protein affects blood vessel and immune cell interactions after COVID-19 infection
Official title: MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
Funded at University of Michigan at Ann Arbor · NIH-11006251 · Data updated 2026-11-12
This study is looking at how a protein called MLL1 affects the way immune cells and blood vessel cells work together after a coronavirus infection, with the goal of finding new ways to help people avoid serious problems like severe breathing issues from COVID-19.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 29, 2023 |
| Project end | September 28, 2025 |
| Funding year | 2024 |
| Award (this year) | $86,392 |
| NIH project number | 5F32HL170540-02 |
| Project ID | NIH-11006251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced severe COVID-19 symptoms, particularly those with ARDS.
✕Less likely to help
Patients who have not been infected with COVID-19 or those with mild symptoms may not receive benefit from this research.
What this research studies
This research investigates the role of the MLL1 protein in the interactions between immune cells and blood vessel cells following infection with the coronavirus. It focuses on understanding how this protein contributes to severe complications like acute respiratory distress syndrome (ARDS) and other inflammatory responses. By examining the mechanisms of endothelial cell activation and the inflammatory response, the research aims to identify potential therapeutic targets to mitigate the harmful effects of COVID-19. Patients may benefit from insights gained into how to better manage or prevent severe outcomes related to COVID-19.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from severe COVID-19 complications.
How similar studies have gone: Other research has shown promising results in understanding the inflammatory responses associated with COVID-19, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Parchment, Nathaniel — University of Michigan at Ann Arbor
- Study coordinator: Parchment, Nathaniel
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
Understanding how DVT forms and heals to prevent vein scarring
This NIH grant supports a physician-scientist to study why deep vein clots form and how vein walls get scarred, with the goal of improving long-term outcomes for patients who develop DVT.
-
Piezo1’s role in blood clotting across vessels
Researchers are exploring how a tiny sensor in blood vessels called Piezo1 influences clot formation, with the aim of reducing clotting risks without causing dangerous bleeding.
-
Oscillatory blood flow and vein valve health to prevent clots
Aimed at understanding how the natural rhythmic blood flow in leg veins protects against clots and whether restoring that flow can prevent dangerous vein clots in hospitalized patients.
-
Local anti-inflammatory therapy to help dissolve clots and prevent vein damage in DVT
Aims to test a local anti-inflammatory treatment to help resolve deep vein clots and reduce long-term vein problems in people with DVT.
-
Precision risk tools for blood clots and bleeding in critically ill children
A pediatric-focused project will use existing data from many hospitals to build and test a risk model that helps doctors decide which very sick kids might benefit from clot-prevention therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.